Post-Gazette president Chamberlain resigning to head pharmaceutical company
Share with others:
Pittsburgh Post-Gazette President Christopher H. Chamberlain is leaving the company to become chief executive officer of Novum Pharmaceutical Research Services, the East Liberty-based medical research company.
Mr. Chamberlain, 40, joined the Post-Gazette in 2008 and was promoted to president in 2009.
"My four years at the Post-Gazette have been a rewarding experience and I am grateful to the Block family for trusting me to lead one of America's great newspapers," Mr. Chamberlain said in a press release.
David M. Beihoff, the former president of newspaper operations for Block Communications Inc., will return as interim general manager of the Post-Gazette.
Allan J. Block, chairman of Block Communications Inc., thanked Mr. Chamberlain for his positive contributions to the Post-Gazette, saying in the same press release, "We wish Chris success in his new career."
Mr. Chamberlain's move to Novum was prompted by the medical research board's decision to split the position of president and CEO. Chris Hendy, 51, who had served in both positions, will now serve only as president.
Mr. Chamberlain's experience heading a company with multi-faceted operations appealed to the Novum leadership, Mr. Hendy said.
"Running a 24/7 operation like the newspaper, which has frequently changing deadlines, very much mirrors our operations," Mr. Hendy said.
The research firm has locations in Houston, Texas and Las Vegas and must adhere to government and industry timetables for clinical research.
Novum employs about 420 workers nationwide, with 180 based in its Pittsburgh headquarters.
Mr. Hendy said his firm hadn't yet figured out how to handle the confusion that comes with two top executives having the same first name.
"But that was a requisite for the position," he said jokingly.
First Published July 11, 2012 10:39 am